Driving Sustainable, Profitable Growth

Q2 2025

August 14, 202 5

CEO Michael Akoh CFO Børge Sørvoll VP Sales Paul Blackburn

Overview Overview

A Norwegian biotech with growth potential Driving Sustainable, Profitable Growth

A provider of novel enzymes for advanced therapies and molecular Targeting segments with considerable growth potential Worldclass Products

World class R&D team • Provide novel enzymes for advanced therapies and molecular diagnostics

diagnostics

No debt – 250 NMOK in Cash reserve

and strong manufacturing capabilities complying to both ISO13485 and GMP Margins above 90% across all products • Strong reputation in Molecular Tools and Bioprocessing segments.

Listed on the Norwegian Stock Exchange

• Net Promoter Score = 84

Customers are life science tools companies, CDMO, Pharma and World class products and reputation in Molecular Tools and Bioprocessing Segment & Customers

segments

US and Europe

Targeting segments with high growth potential
Recuring revenue streams – sticky business Sales of 119 MNOK (2023), positive cash flow and results • Customers are life science tools, CDMO, Pharma and Biotech companies

biotech

55 employees, Headquartered in Tromsø

International management and Board

Talent & Culture

Management team committed to creating a culture where exceptional innovation thrives
World class R&D team
Strong manufacturing capabilities complying to ISO13485 and GMP
Direct sales force in the • 53 employees, HQ in Tromsø
- Direct sales in US & Europe more than 90% of business

Strong Financials

Margins > 90% all products
Recurring revenue streams sticky business
Sales of 108 MNOK (2024)
No debt 240 MNOK in Cash reserve
Listed on the Norwegian Stock Exchange

Agenda

Highlights Q2 & Strategic Priorities

Sales - Biomanufacturing and Molecular Tools

Outlook and Q&A

Highlights Q2 2025

Total revenue up 5% 28.9 MNOK (27.5 MNOK)

M SAN HQ GMP Launched June 16

Biomanufacturing growth accelerates 18.1 MNOK +52% YoY +33% QoQ

EBITDA up 50% 3.9 MNOK (2.6 MNOK)

M SAN HQ most sold product in Q2 Growth of 62% vs Q2 LY

Increased diversified customer portfolio – not dependent on single customers

Driving Sustainable, Profitable Growth

Strategic priorities

From Strong Fundamentals to Sustained Growth

M-SAN HQ GMP

Milestone Achieved: Launch of GMP- grade M-SAN - June 16th 2

Why it matters

Enables use in late-stage and commercial biomanufacturing workflows
Full regulatory documentation package
Complements SAN neo HQ GMP => offering broader salt processing range and performance fit

Commercial potential is large

M-SAN HQ single most sold product in Q2
Unlocks new customer segments in viral vector and vaccine production
GMP-grade format supports greater optionality in pricing

Go-to-Market

Initial shipments to pilot customers first orders received
Full commercial launch during Q3

Sales Update Q2 2025

Q2 Sales - Overview

Biomanufacturing and Molecular Tools

Total sales up slightly in Q2-2025 vs Q2-2024 (26.8 MNOK vs 26.5 MNOK, +1%)

Growth led by strong Biomanufacturing performance

Molecular Tools showing underlying momentum, with gains in Cod UNG and dsDNases

Excluding one key customer, revenue reached its highest level since Q4-2022 - Regional growth: EMEA +75%, US +44%

Q2 Sales - Biomanufacturing

Steady Performance with Expanding Customer Base

Strong Biomanufacturing sales at 18.1 MNOK

GMP product versions continuing to gain market traction

Record quarter for M-SAN HQ, +62% vs previous record (Q3-2023)

M-SAN HQ now the #1 selling product in Biomanufacturing for the first time

Diverse customer base with no dependency on a single account

Sales per area

Q2 Sales - Molecular Tools

Underlying business intact

Revenue softness (8.7M NOK, -40%) in Q2 driven by absence of orders from one key customer which has now returned

USA sales up +70%, fuelled by strong rSAP and Cod UNG momentum

EMEA down -75% due to non-repeat customer impact - excluding this, region shows moderate growth

Core portfolio resilience demonstrated by growth across multiple product lines despite customer timing effects

Sales per area

Customer Diversification

Unique customers and Order Trends

We had slightly fewer Unique Customers vs Q2-2024, driven by a decline in Molecular Tools customers

Segment	Unique Customers	Orders	AOV
Biomanufacturing	-2.7%	+4.3%	+48.7%
Molecular Tools	-20.2%	-20.5%	-27.4%*
Combined	-10.0%	-7.6%	+11.3%

Molecular Tools Q2

*If we exclude one single non repeat customer the AOV is +79.6%

Expenses & Profitability

Profit and loss, Expense development

Change in spend as we transform

Personnel expenses

Reduction Norwegian personnel
Increase in intl. personnel
Reduced capitalisation

Other operating expenses

IT reduced due to lower cost and reversal of cost from previous IT provider
External services impacted by grant related expenses
Continued increase in marketing and commercial efforts
Loss on receivables
Currency headwinds continues

	Q 2		YTD
	2025	2024	2025	2024
Sales revenues	26 8 ,	26 5 ,	50 0 ,	56 5 ,
Other revenues	2 1 ,	1 0 ,	3 8 ,	1 1 ,
Sum revenues	28 9 ,	27 5 ,	53 8 ,	57 6 ,
Cost of materials	1 5 - ,	1 5 - ,	2 8 - ,	2 5 - ,
Change in inventory	0 0 ,	0 6 - ,	0 3 ,	0 9 - ,
Personnel expenses	13 7 - ,	12 9 - ,	32 4 - ,	30 9 - ,
Other operating expenses	9 8 - ,	10 0 - ,	18 7 - ,	18 4 - ,
Sum expenses	-25 0 ,	-25 0 ,	-53 6 ,	-52 7 ,
EBITDA	3 9 ,	2 6 ,	0 1 ,	4 9 ,
Depreciation and amortisation	2 2 - ,	1 5 - ,	4 5 - ,	3 0 - ,
EBIT	1 7 ,	1 1 ,	-4 3 ,	1 9 ,
Net financials	2 3 ,	2 3 ,	4 3 ,	6 5 ,
EBT	4 0 ,	3 4 ,	0 0 ,	7 5 ,

Currency impact

Slightly negative for the quarter

Majority of revenues are in foreign currency
- 63% in USD
- 36% in EURO
- 73% in USD and 27% in EURO for 2024
Currency effect on P&L
- Finance
  - Decrease of 0.5 MNOK in Q2 ( -0.2 MNOK in Q2 2024) and
  - Decrease of 1.1 MNOK for 6M 2025 (+0.2 for 6M 2024)
- Other operating expenses
  - Increaes by 0.2 MNOK for Q2 (increase of 0.1 MNOK Q2 2024) and
- Increase by 0.7 MNOK for 6M 2025 (reduction of ¹⁴ 0.5 MNOK for 6M 2024)

Profitability and expenses

Positive margin

Sales & EBITDA

				YTD
	2025	2024	2025	2024
Sales revenues	26 8 ,	26 5 ,	50 0 ,	56 5 ,
Other revenues	2 1 ,	1 0 ,	3 8 ,	1 1 ,
Sum revenues	28 9 ,	27 5 ,	53 8 ,	6 57 ,

Cost of materials	1 5 - ,	1 5 - ,	2 8 - ,	2 5 - ,
Change in inventory	0 0 ,	0 6 - ,	0 3 ,	0 9 - ,
Personnel expenses	13 7 - ,	12 9 - ,	32 4 - ,	30 9 - ,
Other operating expenses	9 8 - ,	10 0 - ,	18 7 - ,	18 4 - ,
Sum expenses	-25 0 ,	-25 0 ,	-53 6 ,	-52 7 ,
EBITDA	3 9 ,	2 6 ,	0 1 ,	4 9 ,
Depreciation and amortisation	2 2 - ,	1 5 - ,	4 5 - ,	3 0 - ,
EBIT	1 7 ,	1 1 ,	-4 3 ,	1 9 ,
financials Net	2 3 ,	2 3 ,	4 3 ,	5 6 ,
EBT	4 0 ,	3 4 ,	0 0 ,	7 5 ,

Cash flow and short-term investments 4.2 MNOK in changes for Q2*

Cash and STI position

16 *includes changes in STI of +1.1 MNOK

Outlook 2025

The Opportunity

Continued biomanufacturing growth, particularly in the US
Recovery in Molecular Tools driven by incoming orders

CDMO platform partnership

Gradual revenue contribution ramp-up
M-SAN GMP to drive long-term momentum and open new doors

Market development

• Focus on Metagenomic market penetration through partnerships

Product portfolio expansion:

RNA restriction enzyme ET-N1 under development
NGS portfolio development
Positioned for an exciting H2 2025 and onwards with multiple growth drivers ahead

Thank you

Q&A

arcticzymes.com